🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

185 results for “Roche Registration Limited” Clear

  1. RO7234292, RO7234292 Placebo

    Roche Registration Limited

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

  2. RO7247669

    Roche Registration Limited

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  3. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Roche Registration Limited

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  4. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Roche Registration Limited

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  5. RO7790121 Placebo, RO7790121

    Roche Registration Limited

    Moderate to Severe Atopic Dermatitis (AD)

    phase 2 small molecule active

    1 trial

  6. RO7790121 placebo, RO7790121

    Roche Registration Limited

    Moderate to Severe Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  7. RO7790121, RO7790121 placebo/diluent

    Roche Registration Limited

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  8. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Roche Registration Limited

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  9. RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

    Roche Registration Limited

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  10. RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

    Roche Registration Limited

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  11. Rozlytrek 200 mg hard capsules

    Roche Registration Limited

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  12. Rozlytrek, Rozlytrek, Rozlytrek

    Roche Registration Limited

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  13. Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10

    Roche Registration Limited

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  14. Tecentriq 840 mg concentrate for solution for infusion

    Roche Registration Limited

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Roche Registration Limited

    Solid tumors

    phase 2 small molecule active

    1 trial

  16. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Roche Registration Limited

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  17. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Roche Registration Limited

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  18. Trontinemab, Placebo Trontinemab, Flortaucipir F18

    Roche Registration Limited

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  19. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Roche Registration Limited

    Advanced solid tumors

    phase 1 other active

    1 trial

  20. A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS

    Roche Registration Limited

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  21. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

    Roche Registration Limited

    Metastatic Colorectal Cancer

    phase 1 other active

    1 trial

  22. A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma

    Roche Registration Limited

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  23. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Roche Registration Limited

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  24. A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

    Roche Registration Limited

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources